Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma
Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2012/208606 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473425841586176 |
|---|---|
| author | D. Graceffa E. Maiani A. Pace F. M. Solivetti F. Elia C. De Mutiis C. Bonifati |
| author_facet | D. Graceffa E. Maiani A. Pace F. M. Solivetti F. Elia C. De Mutiis C. Bonifati |
| author_sort | D. Graceffa |
| collection | DOAJ |
| description | Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma. |
| format | Article |
| id | doaj-art-d2aef52c0ab641e1b988f93edb6422ce |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-d2aef52c0ab641e1b988f93edb6422ce2025-08-20T03:24:08ZengWileyCase Reports in Rheumatology2090-68892090-68972012-01-01201210.1155/2012/208606208606Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic OligodendrogliomaD. Graceffa0E. Maiani1A. Pace2F. M. Solivetti3F. Elia4C. De Mutiis5C. Bonifati6Centre for the Study and Treatment of Psoriasis, Department of Clinical Dermatology, San Gallicano Dermatological Institute IRCCS, 00144 Rome, ItalyCentre for the Study and Treatment of Psoriasis, Department of Clinical Dermatology, San Gallicano Dermatological Institute IRCCS, 00144 Rome, ItalyDepartment of Neuroscience, Regina Elena National Cancer Institute, 00144 Rome, ItalyRadiodiagnostic Facility, San Gallicano Dermatological Institute IRCCS, 00144 Rome, ItalyRadiodiagnostic Facility, San Gallicano Dermatological Institute IRCCS, 00144 Rome, ItalyRadiodiagnostic Facility, San Gallicano Dermatological Institute IRCCS, 00144 Rome, ItalyCentre for the Study and Treatment of Psoriasis, Department of Clinical Dermatology, San Gallicano Dermatological Institute IRCCS, 00144 Rome, ItalyBevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.http://dx.doi.org/10.1155/2012/208606 |
| spellingShingle | D. Graceffa E. Maiani A. Pace F. M. Solivetti F. Elia C. De Mutiis C. Bonifati Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma Case Reports in Rheumatology |
| title | Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma |
| title_full | Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma |
| title_fullStr | Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma |
| title_full_unstemmed | Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma |
| title_short | Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma |
| title_sort | psoriatic arthritis during treatment with bevacizumab for anaplastic oligodendroglioma |
| url | http://dx.doi.org/10.1155/2012/208606 |
| work_keys_str_mv | AT dgraceffa psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma AT emaiani psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma AT apace psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma AT fmsolivetti psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma AT felia psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma AT cdemutiis psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma AT cbonifati psoriaticarthritisduringtreatmentwithbevacizumabforanaplasticoligodendroglioma |